Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07051031 · ClinicalTrials.gov registry record · Phase 4
COVID-19 Reactogenicity
A Phase 4 study of COVID-19, sponsored by Marcel Curlin.
- Active
- Registry status
- Phase 4
- Development phase
- 1,000
- Enrollment target
- 1
- Study location
NCT07051031: Active Phase 4 study of COVID-19, sponsored by Marcel Curlin.
NCT07051031 is a Phase 4 study of COVID-19 that is active but no longer recruiting, run by Marcel Curlin. The registered enrollment target is 1,000 participants, below the 38,462-participant average among 298 other COVID-19 trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07051031, a Phase 4 study of COVID-19, is active but no longer recruiting, sponsored by Marcel Curlin.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 1,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to compare post-vaccination reactions between the protein-based Novavax vaccine and the mNEXSPIKE mRNA-1283 vaccine. Specifically, the study aims to determine the rate of participant-reported symptoms associated with each type of vaccine.
Primary Outcome
Proportion and number of participants who report at least one systemic symptom (e.g., fever, fatigue, myalgia, headache, chills) within 7 days following COVID-19 booster vaccination, as collected via daily symptom diary.
Conditions Studied
Interventions
- DRUG Nuvaxovid (NVX-CoV2705)
- DRUG mNEXSPIKE mRNA-1283
Study Locations (1)
Oregon
- Oregon Health and Sciences University - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2025-10-01 |
| Est. Completion | 2026-06-14 |
| Phase | Phase 4 |
What the registry record for NCT07051031 still lists
NCT07051031 is an interventional study that assigns participants to a tested intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, below the 38,462-participant average among 298 other COVID-19 trials with a reported enrollment target (97% lower).
The record links to 1 condition, with COVID-19 appearing as the primary indexed condition, and to 2 interventions - of which Nuvaxovid (NVX-CoV2705) is the first listed.
NCT07051031 reports a single indexed study location in Oregon.
Frequently Asked Questions
What is clinical trial NCT07051031 about?
NCT07051031 is a clinical study titled "COVID-19 Reactogenicity". The purpose of this study is to compare post-vaccination reactions between the protein-based Novavax vaccine and the mNEXSPIKE mRNA-1283 vaccine. Specifically, the study aims to determine the rate of participant-reported symptoms associated with each type of vaccine.
What is the current status of trial NCT07051031?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 1,000 participants. The study started on 2025-10-01. Estimated completion is 2026-06-14.
What conditions does trial NCT07051031 study?
This clinical trial studies the following conditions: COVID-19.
What interventions are being tested in trial NCT07051031?
The interventions under investigation include: Nuvaxovid (NVX-CoV2705) (DRUG), mNEXSPIKE mRNA-1283 (DRUG).
Who is sponsoring clinical trial NCT07051031?
This trial is sponsored by Marcel Curlin, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07051031 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07051031's enrollment target sits among peer trials
1,000 71st of 298 higher than 222 of 298 other COVID-19 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other COVID-19 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Pilot Clinical Evaluation of Astepro® Nasal Spray for Management of Early SARS-CoV-2 Infection
RECRUITING · Phase 4
-
Impact of Immunosuppression Adjustment on COVID-19 Vaccination Response in Kidney Transplant Recipients
RECRUITING · Phase 4
-
A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Variant-containing Formulations
RECRUITING · Phase 4
-
Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study
RECRUITING · Phase 4
-
Impact of Reactogenicity of the 2024-2025 COVID-19 Vaccines on Health Care Workers and First Responders in the United States
ACTIVE NOT RECRUITING · Phase 4
-
Vitamin D Supplementation in the Prevention and Mitigation of COVID-19 Infection
ACTIVE NOT RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI